Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Orbital Decompression for Thyroid Eye Disease: Methods, Outcomes, and Complications
source: Eye
year: 2018
authors: Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi SM
summary/abstract:Purpose:
To determine the safety and effectiveness of orbital decompression for thyroid eye disease (TED) in our unit. To put this in the context of previously published literature.
Patients and Methods:
A retrospective case review of all patients undergoing orbital decompression for TED under the care of one orbital surgeon (SMS) between January 2009 and December 2015. A systematic literature review of orbital decompression for TED.
Results:
Within the reviewed period, 93 orbits of 55 patients underwent decompression surgery for TED. There were 61 lateral (single) wall decompressions, 17 medial one-and-a-half wall, 11 two-and-a-half wall, 2 balanced two wall, and 2 orbital fat only decompressions. For the lateral (single) wall decompressions, mean reduction in exophthalmometry (95% confidence interval (CI) was 4.2 mm (3.7-4.8), for the medial one-and-a-half walls it was 2.9 mm (2.1-3.7), and for the two-and-a-half walls it was 7.6 mm (5.8-9.4). The most common complications were temporary postoperative numbness (29% of lateral decompressions, 17% of other bony decompressions, OR 0.50, 95% CI 0.12-2.11) and new postoperative diplopia (9% of lateral decompressions, 39% of other bony decompressions, OR 6.8, 95% CI 1. 5-30.9). Systematic literature searching showed reduction in exophthalmometry for lateral wall surgery of 3.6-4.8 mm, with new diplopia 0-38% and postoperative numbness 12-50%. For other bony decompressions, reduction in exophthalmometry was 2.5-8.0 mm with new diplopia 0-45% and postoperative numbness up to 52%.
Conclusion:
Differing approaches to orbital decompression exist. If the correct type of surgery is chosen, then safe, adequate surgical outcomes can be achieved.
DOI: 10.1038/eye.2017.260
read more full text
myBinderRelated Content
-
Thyroid Surgery for Graves’ Disease and Graves’ OphthalmopathyBackground: Graves' disease is an autoi...
-
“TED Today” Episode 1https://www.facebook.com/ThyroidEyes/vid...
-
Graves’ Orbitopathy as a Rare Disease in Europe: A European Group on Graves’ Orbitopathy (EUGOGO) Positi...Background: Graves' orbitopathy (GO) is...
-
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Communityhttps://www.youtube.com/watch?v=ep3ArKFb...
-
Thyroid Eye Disease and the Role of the TED SpecialistNot all people with thyroid disease have...
-
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
-
Management of Endocrine Disease: Rituximab Therapy for Graves’ Orbitopathy – Lessons From Randomized Con...Rituximab (RTX) use in open-label series...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google